About us
First-in-Class Breakthrough Treatment in Cardiogenic Shock
Our Vision
4TEEN4 Pharmaceuticals GmbH is developing Procizumab, an inhibitor of DPP3 pathway. A breakthrough, first-in-class Phase I asset with clinical proof of concept to restore cardiac function and prevent death due to Cardiogenic Shock an area of high social & economic burden with no effective therapy available.
Our Team
Management
Dr. Andreas Bergmann
Dr. Karine Bourgeois
Prof. Mahir Karakas
Dr. Joachim Struck, CRO
Dr. Kilian von Seldeneck
Advisory Board
Renke Lührs (Chair)
Prof. Alexandre Mebazaa
Gerald Möller
Dr. Christoph Winterhalter
Dr. Ute Kilger
Thomas Krause
Laurent Kirsch
Dr. Marek Kozlowski
Jobs
Shape your Future
Join our Team!
Career at 4TEEN4
4TEEN4 Pharmaceuticals is built on science, innovation, and dedication, where you can use your enthusiasm in changing patients’ lives and creating impact. We are a fast-growing, small-medium enterprise (SME) that grants our employees the ability to grow and shape their career pathways by developing an agile approach.
To achieve our goals, we need to promote our employees’ development.
At 4TEEN4, we offer a highly diverse environment
- By enabling adaptability and promoting an outside-of-the-box way of thinking
- With an established sense of belonging to ensure high engagement and a healthy workplace
Open Positions
Our company is continually looking for highly motivated professionals.
If you are interested in joining our innovative team, please contact us at career@4teen4.de.
Please see our applicant and candidate data protection.
Supported by
The project is funded by the European Social Fund (ESF) and the Federal State of Brandenburg via the Brandeburg Ministry for Labor, Social Affairs, Health, Women and Family (MASGF).
